Assfociations of perfluoroalkyl substances (PFAS) with lower birth weight: An evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK)

Environmental Health Perspectives

Volumn 123, Issue 12, 2015, Pages 1317-1324

  Verner, Marc André ^a,b   Loccisano, Anne E ^c   Morken, Nils Halvdan ^d,e   Yoon, Miyoung ^c   Wu, Huali ^c   McDougall, Robin ^f   Maisonet, Mildred ^g   Marcus, Michele ^h   Kishi, Reiko ⁱ   Miyashita, Chihiro ⁱ   Chen, Mei Huei ^j   Hsieh, Wu Shiun ^j   Andersen, Melvin E ^c   Clewell, Harvey J ^c   Longnecker, Matthew P ^k  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f AEgis Technologies   (United States)

^g EAST TENNESSEE STATE UNIVERSITY   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ HOKKAIDO UNIVERSITY   (Japan)

^j NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^k NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKANESULFONIC ACID; FLUOROCARBON; OCTANOIC ACID DERIVATIVE; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; POLLUTANT;

ADULT; BIOLOGICAL MODEL; BIRTH WEIGHT; COMPUTER SIMULATION; DRUG EFFECTS; EPIDEMIOLOGY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MATERNAL EXPOSURE; META ANALYSIS; MONTE CARLO METHOD; PHARMACOKINETICS; POLLUTANT; PREGNANCY; TOXICITY;

ADULT; ALKANESULFONIC ACIDS; BIRTH WEIGHT; CAPRYLATES; COMPUTER SIMULATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENVIRONMENTAL POLLUTANTS; FEMALE; FLUOROCARBONS; GLOMERULAR FILTRATION RATE; HUMANS; MATERNAL EXPOSURE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PREGNANCY;

EID: 84938871333     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1408837     Document Type: Article

References (48)

1. Agency for Toxic Substances and Disease Registry (ATSDR). 2009. “Draft Toxicological Profile for Perfluoroalkyls.” Available: http://www.atsdr.cdc.gov/toxprofiles/tp200.pdf [accessed 26 October 2015],
2. Akahori Y, Masuyama H, Hiramatsu Y. 2012. The correlation of maternal uric acid concentration with small-for-gestational-age fetuses in normo-tensive pregnant women. Gynecol Obstet Invest 73(2):162-167.
3. Al-Delaimy WK, Jansen EH, Peeters PH, van der Laan JD, van Noord PA, Boshuizen HC, et al. 2006. Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers 11(4):370–382.
4. Apelberg BJ, Witter FR, Herbstman JB, Calafat AM, Halden RU, Needham LL, et al. 2007. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ Health Perspect 115:1670-1676; doi:10.1289/ehp.10334.
5. Aras S, Varli M, Uzun B, Atli T, Keven K, Turgay M. 2012. Comparison of different glomerular filtration methods in the elderly: which formula provides better estimates? Ren Fail 34(4):435-441.
6. Bartell SM, Calafat AM, Lyu C, Kato K, Ryan PB, Steenland K. 2010. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect 118:222-228; doi:10.1289/ehp.0901252.
7. Bosma RJ, van der Heide JJ, Oosterop EJ, de Jong PE, Navis G. 2004. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 65(1):259-265.
8. Brede E, Wilhelm M, Goen T, Muller J, Rauchfuss K, Kraft M, et al. 2010. Two-year follow-up biomonitoring pilot study of residents’ and controls’ PFC plasma levels after PFOA reduction in public water system in Arnsberg, Germany. Int J Hyg Environ Health 213(3):217-223.
9. Burmaster DE, Anderson PD. 1994. Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments. Risk Anal 14(4):477-481.
10. CDC (Centers for Disease Control and Prevention). 2013. National Health and Nutrition Examination Survey. 2009-2010 Data Documentation, Codebook, and Frequencies. Polyfluoroalkyl Chemicals (PFC_F). Available: http://wwwn.cdc.gov/nchs/nhanes/2009-2010/PFC_F.htm[accessed 11 August 2014].
11. Chen MH, Ha EH, Wen TW, Su YN, Lien GW, Chen CY, et al. 2012. Perfluorinated compounds in umbilical cord blood and adverse birth outcomes. PLoS One 7(8):e42474; doi:10.1371/journal.pone.0042474.
12. Davison JM, Hytten FE. 1974. Glomerular filtration during and after pregnancy. J Obstet Gynaecol Br Commonw 81(8):588-595.
13. Dhillon S, Kostrzewski AJ, eds. 2006. Clinical Pharmacokinetics. 1st ed. London, UK:Pharmaceutical Press.
14. Dunlop W. 1981. Serial changes in renal haemo-dynamics during normal human pregnancy. Br J Obstet Gynaecol 88(1):1-9.
15. Dunlop W, Furness C, Hill LM. 1978. Maternal haemoglobin concentration, haematocrit and renal handling of urate in pregnancies ending in the births of small-for-dates infants. Br J Obstet Gynaecol 85(12):938-940.
16. Duvekot JJ, Cheriex EC, Pieters FA, Menheere PP, Schouten HJ, Peeters LL. 1995. Maternal volume homeostasis in early pregnancy in relation to fetal growth restriction. Obstet Gynecol 85(3):361-367.
17. Egger M, Schneider M, Davey Smith G. 1998. Spurious precision? Meta-analysis of observational studies. BMJ 316(7125):140-144.
18. Fei C, McLaughlin JK, Tarone RE, Olsen J. 2007. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect 115:1677-1682; doi:10.1289/ehp.10506.
19. Fromme H, Mosch C, Morovitz M, Alba-Alejandre I, Boehmer S, Kiranoglu M, et al. 2010. Pre- and postnatal exposure to perfluorinated compounds (PFCs). Environ Sci Technol 44(18):7123-7129.
20. Gibson HM. 1973. Plasma volume and glomerular filtration rate in pregnancy and their relation to differences in fetal growth. J Obstet Gynaecol Br Commonw 80(12):1067-1074.
21. Glynn A, Berger U, Bignert A, Ullah S, Aune M, Lignell S, et al. 2012. Perfluorinated alkyl acids in blood serum from primiparous women in Sweden: serial sampling during pregnancy and nursing, and temporal trends 1996-2010. Environ Sci Technol 46(16):9071-9079.
22. Hamm MP, Cherry NM, Chan E, Martin JW, Burstyn I. 2010. Maternal exposure to perfluorinated acids and fetal growth. J Expo Sci Environ Epidemiol 20(7):589-597.
23. Health Canada. 2013. Second Report on Human Biomonitoring of Environmental Chemicals in Canada. Ottawa, Ontario, Canada:Health Canada.
24. Johnson PI, Sutton P, Atchley DS, Koustas E, Lam J, Sen S, et al. 2014. The Navigation Guide— evidence-based medicine meets environmental health: systematic review of human evidence for PFOA effects on fetal growth. Environ Health Perspect 122:1028-1039; doi:10.1289/ehp.1307893.
25. Kim S, Choi K, Ji K, Seo J, Kho Y, Park J, et al. 2011. Trans-placental transfer of thirteen perfluorinated compounds and relations with fetal thyroid hormones. Environ Sci Technol 45(17):7465-7472.
26. Kim SK, Lee KT, Kang CS, Tao L, Kannan K, Kim KR, et al. 2011. Distribution of perfluorochemicals between sera and milk from the same mothers and implications for prenatal and postnatal exposures. Environ Pollut 159(1):169-174.
27. Knopp RH, Bergelin RO, Wahl PW, Walden CE. 1985. Relationships of infant birth size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and body weight at 36 weeks gestation. Diabetes 34(suppl 2):71-77.
28. Koetje PM, Spaan JJ, Kooman JP, Spaanderman ME, Peeters LL. 2011. Pregnancy reduces the accuracy of the estimated glomerular filtration rate based on Cockroft-Gault and MDRD formulas. Reprod Sci 18(5):456-462.
29. Lam J, Koustas E, Sutton P, Johnson PI, Atchley DS, Sen S, et al. 2014. The Navigation Guide— evidence-based medicine meets environmental health: integration of animal and human evidence for PFOA effects on fetal growth. Environ Health Perspect 122:1040-1051; doi:10.1289/ehp.1307923.
30. Laughon SK, Catov J, Roberts JM. 2009. Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women. Am J Obstet Gynecol 201(6):582e1-e582.e6.
31. Loccisano AE, Longnecker MP, Campbell JL Jr, Andersen ME, Clewell HJ III. 2013. Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A 76(1):25-57.
32. Maisonet M, Terrell ML, McGeehin MA, Christensen KY, Holmes A, Calafat AM, et al. 2012. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ Health Perspect 120:1432-1437; doi:10.1289/ehp.1003096.
33. McNally K, Cotton R, Loizou GD. 2011. A workflow for global sensitivity analysis of PBPK models. Front Pharmacol 2:31; doi:10.3389/fphar.2011.00031.
34. Monroy R, Morrison K, Teo K, Atkinson S, Kubwabo C, Stewart B, et al. 2008. Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ Res 108(1):56-62.
35. Morken NH, Travlos GS, Wilson RE, Eggesbo M, Longnecker MP. 2014. Maternal glomerular filtration rate in pregnancy and fetal size. PLoS One 9(7):e101897; doi:10.1371/journal.pone.0101897.
36. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115(9):1298-1305; doi:10.1289/ehp.10009.
37. Olsen GW, Butenhoff JL, Zobel LR. 2009. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol 27(3-4):212-230.
38. Savitz DA, Stein CR, Bartell SM, Elston B, Gong J, Shin HM, et al. 2012a. Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community. Epidemiology 23(3):386-392.
39. Savitz DA, Stein CR, Elston B, Wellenius GA, Bartell SM, Shin HM, et al. 2012b. Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio Valley. Environ Health Perspect 120:1201-1207; doi:10.1289/ehp.1104752.
40. Shankar A, Xiao J, Ducatman A. 2011. Perfluoroalkyl chemicals and chronic kidney disease in US adults. Am J Epidemiol 174(8):893-900.
41. Tidman M, Sjostrom P, Jones I. 2008. A comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two. Nephrol Dial Transplant 23(1):154-160.
42. U.S. EPA (U.S. Environmental Protection Agency). 2006. PFOA Stewardship Program Description. Available: http://www.epa.gov/oppt/pfoa/pubs/stewardship/pfoastewardshipbasics.html [accessed 15 August 2014].
43. Verner MA, McDougall R, Glynn A, Andersen ME, Clewell HJ III, Longnecker MP. 2013. Is the relationship between prenatal exposure to PCB-153 and decreased birth weight attributable to pharmacokinetics? Environ Health Perspect 121:1219-1224; doi:10.1289/ehp.1206457.
44. Washino N, Saijo Y, Sasaki S, Kato S, Ban S, Konishi K, et al. 2009. Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. Environ Health Perspect 117:660-667; doi:10.1289/ehp.11681.
45. Watkins DJ, Josson J, Elston B, Bartell SM, Shin HM, Vieira VM, et al. 2013. Exposure to perfluoroalkyl acids and markers of kidney function among children and adolescents living near a chemical plant. Environ Health Perspect 121:625-630; doi:10.1289/ehp.1205838.
46. Whitworth KW, Haug LS, Baird DD, Becher G, Hoppin JA, Skjaerven R, et al. 2012. Perfluorinated compounds in relation to birth weight in the Norwegian Mother and Child Cohort Study. Am J Epidemiol 175(12):1209-1216.
47. Willett WC. 1990. Nutritional Epidemiology. New York:Oxford University Press.
48. Yoon M, Schroeter JD, Nong A, Taylor MD, Dorman DC, Andersen ME, et al. 2011. Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. Toxicol Sci 122(2):297-316.